News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Prolias Announces Strategic Technology Acquisition for Human Therapeutic Antibodies From University of Maryland Biotechnology Institute



1/7/2010 8:52:55 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease, today announced a strategic acquisition of technology from the University of Maryland Biotechnology Institute (UMBI). The new technology will extend Prolias’ discovery platform, FIoNATM, by providing a platform for the creation of fully human, recombinant antibodies from diverse, endogenous antibody sources.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES